Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
02 2023
Historique:
revised: 02 11 2022
received: 23 09 2022
accepted: 23 11 2022
pubmed: 26 11 2022
medline: 17 1 2023
entrez: 25 11 2022
Statut: ppublish

Résumé

The FOS gene family has been implicated in tumourigenesis across several tumour types, particularly mesenchymal tumours. The rare fibrous tumour desmoplastic fibroblastoma is characterised by overexpression of FOSL1. However, previous studies using cytogenetic and molecular techniques did not identify an underlying somatic change involving the FOSL1 gene to explain this finding. Prompted by an unusual index case, we report the discovery of a novel FOSL1 rearrangement in desmoplastic fibroblastoma using whole-genome and targeted RNA sequencing. We investigated 15 desmoplastic fibroblastomas and 15 fibromas of tendon sheath using immunohistochemistry, in situ hybridisation and targeted RNA sequencing. Rearrangements in FOSL1 and FOS were identified in 10/15 and 2/15 desmoplastic fibroblastomas respectively, which mirrors the pattern of FOS rearrangements observed in benign bone and vascular tumours. Fibroma of tendon sheath, which shares histological features with desmoplastic fibroblastoma, harboured USP6 rearrangements in 9/15 cases and did not demonstrate rearrangements in any of the four FOS genes. The overall concordance between FOSL1 immunohistochemistry and RNA sequencing results was 90%. These findings illustrate that FOSL1 and FOS rearrangements are a recurrent event in desmoplastic fibroblastoma, establishing this finding as a useful diagnostic adjunct and expanding the spectrum of tumours driven by FOS gene family alterations. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Identifiants

pubmed: 36426824
doi: 10.1002/path.6038
pmc: PMC10107450
doi:

Substances chimiques

USP6 protein, human EC 3.4.19.12
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-124

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 223135/Z/21/Z
Pays : United Kingdom

Informations de copyright

© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Références

Diagn Pathol. 2016 Aug 11;11(1):75
pubmed: 27515856
J Biol Chem. 2017 Dec 29;292(52):21282-21290
pubmed: 29150442
Nat Commun. 2018 Jun 1;9(1):2150
pubmed: 29858576
Lab Invest. 2012 May;92(5):735-43
pubmed: 22411068
Mod Pathol. 2021 Oct;34(10):1876-1888
pubmed: 34088995
Oncogene. 2001 Nov 8;20(51):7563-72
pubmed: 11709728
Mol Cell Biol. 2007 Jun;27(11):3936-50
pubmed: 17371847
Genes Chromosomes Cancer. 2014 Nov;53(11):951-9
pubmed: 25043949
Mol Cell Biol. 1983 May;3(5):914-21
pubmed: 6306448
J Pathol. 2014 Apr;232(5):534-40
pubmed: 24374978
Cancer Res. 2017 Nov 1;77(21):e31-e34
pubmed: 29092934
Oncogene. 2001 Apr 30;20(19):2401-12
pubmed: 11402336
Genes Chromosomes Cancer. 2015 Sep;54(9):565-74
pubmed: 26173738
Histopathology. 2016 Dec;69(6):1012-1020
pubmed: 27442992
Genome Res. 2021 Mar;31(3):448-460
pubmed: 33441414
Int J Mol Sci. 2022 Jan 28;23(3):
pubmed: 35163444
In Vivo. 2021 Jan-Feb;35(1):69-73
pubmed: 33402451
Cell. 2000 Sep 29;103(1):29-40
pubmed: 11051545
Br J Cancer. 2022 Jul;127(1):137-144
pubmed: 35449451
Am J Surg Pathol. 2019 Dec;43(12):1661-1667
pubmed: 31490237
Mod Pathol. 2007 Apr;20(4):482-96
pubmed: 17334349
Immunol Rev. 2005 Dec;208:126-40
pubmed: 16313345

Auteurs

Solange De Noon (S)

Research Department of Pathology, University College London Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Robert Piggott (R)

Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Jamie Trotman (J)

Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

John A Tadross (JA)

Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Matthew Fittall (M)

Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Division of Oncology, University College London Cancer Institute, London, UK.

Debbie Hughes (D)

Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, London, UK.

Hongtao Ye (H)

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Emani Munasinghe (E)

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Matthew Murray (M)

Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Department of Pathology, University of Cambridge, Cambridge, UK.

Roberto Tirabosco (R)

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Fernanda Amary (F)

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Nicholas Coleman (N)

Department of Pathology, University of Cambridge, Cambridge, UK.

James Watkins (J)

Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Michael Hubank (M)

Clinical Genomics, The Royal Marsden NHS Foundation Trust, London, UK.
Molecular Pathology, The Institute of Cancer Research, London, UK.

Patrick Tarpey (P)

Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Sam Behjati (S)

Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Cellular Genetics, Wellcome Sanger Institute, Hinxton, UK.
Department of Paediatrics, University of Cambridge, Cambridge, UK.

Adrienne M Flanagan (AM)

Research Department of Pathology, University College London Cancer Institute, London, UK.
Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH